Reason reports back from Rejuvenation Startup Summit 2024
Fight Aging! - 13-May-2024A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials
Join the club for FREE to access the whole archive and other member benefits.
Daily news and insights on research, investments and technologies on life extension
We bring together innovators and investors to commercialise the companies that will form the longevity economy.
There are already 100+ rejuvenation biotechs working on unique therapies and building R&D pipelines to increase healthspan and lifespan.
At the same time, all around the world, innovators are releasing nanobots, reprogramming nerve signals and applying AI to create exciting and scalable contributions to human Longevity.
Visit website: https://www.longevity.technology/
Details last updated 12-Sep-2019
A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials
Longevity.Technology releases its annual longevity investment report 2023
Key investors raise funding to support longevity sector
18-Jan-2023
Phil talks about shaping the longevity industry at this Oxford Society of Ageing and Longevity event (FREE)
Longevity Technology discusses senescent cells with Steve Matheson, CEO of Combilytics (YouTube)
Biotech firm uses AI and robotics to test drugs on real human tissues, not animals
The company is still in early stages but attracting strong investor interest
Dorian’s anti-senescence tech adds firepower to Altos Labs’ rejuvenation strategy
Somite AI uses DeltaStem to speed up and scale stem cell engineering
Private funding supports global scientists tackling Alzheimer’s, vision loss, and glaucoma
Biotech startup raises $65M to develop RNA therapies that reprogram disease-driving cell states
AI-driven health platform gears up for launch with cutting-edge longevity data
The biotech company aims to target the root causes of ageing to develop therapies to extend lifespan
PhotoPharmics secures $6 million to advance its home-based Celeste device
HepaRegeniX advances trials for a novel liver regeneration therapy
A next-gen retinal implant offers new hope for vision loss from macular degeneration
It avoids common delivery problems and enters Phase 1 trials in 2025
Scandinavian biotech targets fibrosis with novel scar-blocking therapies
It uses blood tests to find early health risks and gives personalised advice
Clinical trials are beginning, backed by major investors like Novo Holdings
Targeted protein degradation tackles harmful aggregates while sparing healthy proteins
The biotech firm accelerates clinical trials for TN-201 and TN-401, targeting genetic heart disease
naturalX backs startups reshaping wellness and prevention
The Dutch startup is using ion channel research and advanced tech to develop new treatments
Backed by AI and genetics, Junevity targets age-related diseases